Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07867288
PHASE1

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001

Sponsor: Haya Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.

Official title: A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-10

Completion Date

2027-03

Last Updated

2026-10-27

Healthy Volunteers

Yes

Interventions

DRUG

HTX-001

HTX-001 is an investigational antisense oligonucleotide (ASO)

Locations (3)

Lahey Clinic

Boston, Massachusetts, United States

Saint Luke's Health System

Kansas City, Missouri, United States

The Lindner Research Center at The Christ Hospital

Cincinnati, Ohio, United States